Proposed Measures for Antipsychotic Medication Use
Antipsychotic medication use is an area of interest for measures development given their increased use in children and adolescents and potentially harmful health effects. While these medications offer the potential for effective treatment of psychiatric disorders, they can also increase a child's risk for developing health concerns such as metabolic and physical complications. Working in coordination with MEDNET, another AHRQ-funded effort to promote quality, NCQA developed a set of measures assessing the use of antipsychotic medications in a general population of children as well as those in the foster care system. The measures will be considered for use by state and federal programs.
NCINQ is seeking feedback to assess the measures' importance, usability and understandability. Attached specifications are for state-level reporting using administrative data. Measures assess whether needed follow-up care occurred in children who are taking antipsychotic medications as well as potential overuse of medications, which reflect concerns heard from stakeholders including state Medicaid directors, consumer advocates and families.
Measures 
About NCINQ's Measure Development Process
NCINQ employs a multi-step process that includes working with a wide range of stakeholders to prioritize measure topics and define and test measures. NCINQ considers the importance and prevalence of the condition being assessed, whether measures inform access to care or quality improvement efforts, and the feasibility of collecting and reporting the data. NCINQ's stakeholders include patients and families, clinicians, state Medicaid officials, and experts in the field of child health. This process ensures measures are reasonable and important to those using them.
Feedback Needed
While reviewing this measure set, questions to consider include the following.
• Are these measures important to inform state-level quality improvement activities?
• Do these measures address critical concerns for Medicaid and CHIP?
• Do these measures address critical concerns for children in the foster care system?
• Are the measure specifications clear and understandable?
• Is information required to calculate these measures available?
• Do these measures reflect realistic clinical processes and workflow? Additional questions are listed in the draft specifications document.
Supporting Documents Draft Specifications, Literature and Guideline Review, Preliminary Performance Results

NCINQ thanks its advisory panels for their input on this work.
Draft Document for NCINQ 2013 Public Comment -Obsolete After May 17, 2013 Data show that antipsychotic prescribing for children is increasing. The frequency of prescribing antipsychotics increased almost fivefold between 1996 to 2002, from 8.6 per 1000 children to 39.4 per 1000 (Seida et al., 2012) . Data from a national prescription database showed that antipsychotic use among those aged 0-17 increased 51 percent, the largest increase of any age group (Cascade et al., 2006) . A review of prescribing patterns in seven state Medicaid programs found that the percentage of youth aged 6-17 filling at least one antipsychotic prescription increased from 2.7 percent in 2001 to 4.2 percent in 2004 (Crystal et al., 2009) . A study of 16 state Medicaid programs found that the percentage of enrollees under age 19 on an antipsychotic varied greatly according to eligibility category, ranging from 0.6 percent for state Children's Health Insurance Program (CHIP) enrollees to 13.4 percent for those eligible under Aged, Blind and Disabled provisions; the rate for foster care youth was 12.4 percent (Medicaid Medical Directors Learning Network and Rutgers Center for Education and Research on Mental Health Therapeutics, 2010).
While overall antipsychotic prescribing is increasing, use of atypical antipsychotics also saw dramatic increases in use. Atypical antipsychotics doubled their share of all psychotropic medication prescriptions among privately insured youth between 1997 and 2000, from 2.4 percent of all psychotropic prescriptions to 5.1 percent. Atypical antipsychotics also have the greatest mean prescription cost ($132) of any psychotropic medication (Martin & Leslie, 2003) .
Analysis of the National Ambulatory Medical Care Survey found that predictors of antipsychotic use among youth included male sex, public insurance, and a diagnosis of psychosis, tic disorder, or pervasive development disorder or mental retardation (Olfson et al., 2006) .
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Opportunity for Improvement
The increase in antipsychotic prescribing among youth is associated with the availability of atypical antipsychotic medications, which have different side effect profiles from the conventional antipsychotics (Olfson et al., 2006) . Atypical antipsychotics tend to be less sedating and pose a lower risk of movement disorders such as tardive dyskinesia; however these agents are more likely to be associated with metabolic side effects such as weight gain and diabetes (Correll et al., 2009; Toren et al., 2004) . In addition to the concerns about side effects associated with antipsychotic medications, there is concern about the increasing use of these agents among young children. A study of youth with private insurance found that almost 25 percent of youth on an atypical antipsychotic were nine years old or younger (Curtis et al., 2005) , and a study of preschoolers insured through Medicaid found that 17 percent of those on any psychotropic medication were on an antipsychotic, with 96 percent of those on an atypical antipsychotic (Zito et al., 2007) . Studies have also shown that atypical antipsychotics are commonly used for conditions other than those approved by the FDA for children; in 2004, over 70 percent of youth on antipsychotics did not have a diagnosis associated with an approved FDA indication (Crystal et al., 2009) . While some evidence supports the efficacy of antipsychotics in youth for certain narrowly defined conditions, less is known about the safety and effectiveness of antipsychotic prescribing patterns in community use (e.g., combinations of medications, off-label prescribing, or dosing outside of recommended ranges).
In the last ten years, the use of psychoactive medication among children and adolescents has increased, especially among those in foster care. According to one study, one in ten school-aged children (ages 6 to 11) and one in six adolescents (ages 12 to 18) were taking antipsychotics by 2007. The study looked at 686,000 foster-care children 
Methods
The evidence search focused on antipsychotic use among children and adolescents under the age of 18 years. The search was not restricted by care setting and included all conditions for which an AACAP practice parameter is available (e.g. schizophrenia, bipolar disorder, depression, conduct disorder, etc.).
Guidelines Search
To identify relevant guidelines, we searched primarily the National Guidelines Clearinghouse and Guidelines International Network. Out of scope and duplicate guidelines (e.g., guidelines that were published in multiple journals) were excluded. A summary of the search string for the guidelines search is provided in Table 1 . Systematic Review Search Systematic reviews (including meta-analyses) for concepts with no guidelines with action-oriented statements were sought using PubMed, the Cochrane Database of Systematic Reviews, PsychInfo, and the Agency for Healthcare Research and Quality (AHRQ) Evidence Reports on mental health conditions and substance abuse. Out of scope or duplicate reviews were excluded (e.g., reviews that were published in multiple journals or found in multiple databases). A summary of the search string for the systematic review search is provided in Table 2 . Overall Results
Guidelines Search Results
The National Guideline Clearinghouse identified four practice parameters published by AACAP that reference antipsychotics for youth: obsessive compulsive disorder, bipolar disorder, oppositional defiant disorder, and depressive disorders. A search of the AACAP website yielded two additional practice parameters: schizophrenia (published 2001 and hence not included in the NCG search results) and the use of atypical antipsychotic medications (approved by the AACAP Council but not yet published and therefore not present in the NGC search results). The Guidelines International Network identified one guideline, the AHRQ "Off-label Use of Atypical Antipsychotic Drugs;" however upon review, this document is best characterized as an evidence review rather than a guideline and is not specific to (Kennedy et al., 2007) concluded, "There are few relevant trials and, presently, there is little conclusive evidence regarding the effects of antipsychotic medication for those with early onset schizophrenia. Some benefits were identified in using the atypical antipsychotic clozapine compared with haloperidol but the benefits were offset by an increased risk of serious adverse effects. Larger, more robust, trials are required." We identified two published systematic reviews that address use of antipsychotics in youth more broadly (Jensen et al. 2007; Seida et al., 2012) . These reviews focused on the efficacy of antipsychotic treatment. All note that the current body of evidence is "thin," with significant gaps. No reviews spoke to antipsychoitc polypharmacy, dose, or use in preschoolers. The authors of the most recent study (Seida et al., 2012) 
Measure-Specific Results
In the sections below, we briefly describe each measure concept and the guidelines from our overall search results that apply. We also describe our preliminary conclusions and the implications considered during development.
MEASURE CONCEPT #1: Children on Higher than Recommended Doses of Antipsychotics
Draft Description: Children and adolescents 20 years of age and younger on any antipsychotic medication during the measurement year who received a higher than recommended dose based on Food and Drug Administration recommendations.
Importance
Worrisome adverse effects of atypical (second generation) antipsychotics have been documented even at low doses, including excessive weight gain resulting in obesity, large increases in prolactin, and higher risk of extrapyramidal side effects including tardive dyskinesia. Studies of atypical antipsychotics in youth have demonstrated equal or worsening response when higher doses are compared to lower doses (Haas et al., 2009; Schooler et al, 2005) . As of March 1, 2012, 6.91 percent of youth under age 18 years in the New York State Medicaid behavioral health population (defined as at least one behavioral health service, diagnosis, or medication in the index year) on an antipsychotic were prescribed a higher than recommended dose.
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Food and Drug Administration (FDA)-recommended doses for youth are available only for certain antipsychotics. Measures developed in New York State for the Psychiatric Services and Clinical Knowledge Enhancement System (PSYCKES) used a hierarchically determined maximum recommended dose based on 1) the FDA recommended maximum dose for children and/or adolescents, 2) the maximum dose specified in the Texas Department of Family Services Psychotropic Medication Utilization Parameters for Foster Children, 3) the maximum dose specified in a standard pediatric psychopharmacology textbook, 4) if no maximum recommended doses for children were found in the above sources, the FDA maximum recommended dose for adults was used. Weight-based measures used a standard calculation.
Guidelines Found
Organization ( 
MEASURE CONCEPT #2: Use of Antipsychotics in Very Young Children
Draft Description: Children 5 years of age and younger who are on at least one antipsychotic medication during the measurement year.
Importance
During the past decade, rates of prescription of psychotropic medications to preschool children have risen for both Medicaid and privately insured groups. The rate of antipsychotic use in privately insured preschoolers more than doubled from 1999 to (Olfsen et al., 2010 , and a study of preschoolers insured through Medicaid found that 17 percent of those on any psychotropic medication were on an antipsychotic, with 96 percent of those on an atypical antipsychotic (Zito et al., 2007) . As of September 1, 2011, 2.0 percent of youth under age 18 in the New York State Medicaid behavioral health population on an antipsychotic were younger than 6 years old.
The effectiveness, safety, and appropriate dosing of antipsychotics in preschool children remain unknown. Worrisome adverse effects of atypical antipsychotics have been documented even at low doses, including excessive weight gain 
MEASURE CONCEPT #3: Use of Multiple Concurrent Antipsychotics in Children
Draft Description: Children and adolescents 20 years of age and younger on any antipsychotic medication during the measurement year who were on two or more concurrent antipsychotic medications for longer than 90 days.
Importance
Although there is little empirical evidence to support its use, the use of multiple concurrent antipsychotics is becoming an increasingly frequent practice in the mental health treatment of youth. One study of a large state Medicaid fee-forservice program found that 7 percent of children age 6-17 on any antipsychotic were prescribed two or more antipsychotics for longer than 60 days (Constantine et al., 2010 
MEASURE CONCEPT #4: Use of Antipsychotics in Children without a Primary Indication
Draft Description: Children and adolescents 20 years of age and younger on any antipsychotic medication during the measurement year who do not have a primary (first line) indication for antipsychotic use.
Importance
Use of antipsychotics without a FDA indication is increasing, despite increased awareness of significant side effect burden associated with these medications. For instance, one analysis of NYS Medicaid data found that almost half of the individuals on antipsychotics did not have any claim with a diagnosis that included psychotic features or autism in the year prior (Finnerty et al., available upon request).
The use of antipsychotics for conditions without psychosis has limited evidence of effectiveness and is expensive (Alexander et al., 2011) . A recent AHRQ Comparative Effectiveness Review update of off-label use of atypical antipsychotics concluded that the evidence of efficacy of atypical antipsychotics for off-label uses was insufficient to reach conclusions about the usefulness of these agents, particularly since there are few studies that detail the adverse side effect burden of atypical antipsychotics among children and adolescents (Magilone et al., 2011 General "The evidence of efficacy of atypical antipsychotics for offlabel uses is insufficient to reach conclusions about the usefulness of these agents."
Varied from low to moderate depending on the specific agent and condition *Guideline Organization's assessment of evidence specified in guideline
Conclusion
There is no consensus about the use of antipsychotics for children without a primary indication in general . To the extent this issue is addressed in guidelines, the focus is on the use of atypical antipsychotics. The AACAP Practice Parameter on the use of atypical antipsychotics encourages clinicians to consider other treatment modalities before initiating these medications in the absence of FDA indication. A review by AHRQ, though not restricted to youth, found that the evidence was insufficient to reach conclusions about the efficacy of atypical antipsychotics for off-label use. General Principles section includes the statement, "The frequency of clinician follow-up with the patient should be appropriate for the severity of the child's condition and adequate to monitor response to treatment including: symptoms, behavior, function, and potential medication side effects." Not specified *Guideline organization's assessment of evidence specified in guideline
Conclusions
Although there is no consensus in the literature on the appropriate number or time period for follow-up visits for youth prescribed antipsychotic medication, several published guidelines for youth mention the importance of monitoring for side effects, which suggests the need for follow-up care visits. The HEDIS measure of follow-up care for children prescribed ADHD medication has served as a model for children prescribed antipsychotics.
Jensen, P. S., Hinshaw, S. P., Swanson, J. M., Greenhill, L. L., Conners, C. K., Arnold, L. E., Abikoff H et al. (2001 
MEASURE CONCEPT #6: Metabolic Screening for Children on Antipsychotics
Draft Description: Children and adolescents 20 years of age and younger on any antipsychotic medication during the measurement year who had metabolic screening documented, including testing for blood glucose and cholesterol.
Importance
Increasing concerns regarding obesity and diabetes emergence in younger populations (Eisenmann, 2003) are heightened for youth prescribed antipsychotic medications due to adverse metabolic and other physical effects (Pringsheim et al., 2011) . A multi-year study of youth enrolled in three health maintenance organizations found that exposure to atypical antipsychotics was associated with a fourfold risk of diabetes in the following year, compared to children not prescribed psychotropic medication (Andrade et al., 2011) .
Despite these concerns, a study of Medicaid-enrolled children in three states found that only 31 percent of youth starting an atypical antipsychotic received a glucose test (Morrato et al., 2010 
MEASURE CONCEPT #7: Access to Psychosocial Care for Children on Antipsychotics
Draft Description: Children and adolescents 20 years of age and younger on any antipsychotic medication during the measurement year with documentation of receiving any psychosocial care.
Importance
There is evidence for the efficacy of psychosocial interventions for youth with certain conditions who are frequently prescribed antipsychotics, including ADHD (e.g. Jensen et al., 2001 ) and early-onset schizophrenia (Schimmelman et al., 2013) . However, research suggests that mental health services such as therapy are decreasing among youth, even as use of antipsychotic medications is increasing (Olfson et al., 2010) . One study of Medicaid-enrolled children starting an antipsychotic medication found that almost one-third did not receive concurrent psychosocial therapy .
Current standards of care for several psychiatric conditions recommend the use of psychosocial interventions prior to or concurrent with pharmacological treatments. Monitoring the use of psychosocial interventions for youth prescribed antipsychotics may provide important information about access to evidence-based care for children and families.
Guidelines Found
Organization ( General Principles section includes the statement, "The role of non-pharmacological interventions should be considered before beginning a psychotropic medication, except in urgent situations … when there is marked disturbance of psychophysiological functioning … or when the child shows marked anxiety, isolation, or withdrawal." Not specified *Guideline organization's assessment of evidence specified in guideline
Conclusions
Many guidelines endorse the use of psychosocial interventions for certain conditions prior to or concurrent with medications. American Academy of Child and Adolescent Psychiatry Practice Parameters for schizophrenia, bipolar disorder, and oppositional defiant disorder emphasize the importance of psychosocial interventions, as do the Treatment Recommendations for Aggression in Youth (Pappadopulos et al., 2003) . One guideline for pharmacological treatments for very young children recommended that psychotherapy should generally be tried before medication, and should continue if pharmacological therapy is initiated . In addition to comments on individual measures, we are seeking input on three global issues that would affect the measure set. Commenters can respond directly to these issues by selecting the relevant "Question:" items listed within the drop-down list of measure names.
Summary of Measure Concept Evidence Scan Results
Question 1. Eligibility
• We have specified a continuous eligibility requirement of three months but seek feedback on a continuous eligibility requirement of three months, twelve months or none.
• Medication related measures can be calculated without eligibility criteria -should this approach be used to be as inclusive as possible?
Question 2. Definition of antipsychotic medication use
• Options include basing denominator eligibility on the presence of at least one antipsychotic prescription OR a certain number of prescriptions during a period of time (e.g., at least two antipsychotic prescriptions within a 90 day period).
Question 3. Foster Care Population
• For example, should a different continuous eligibility requirement be used for children in foster care?
• Are there are other relevant issues that justify specifying the measures differently? 
Children on Higher Than Recommended Doses of Antipsychotics
Measure Description
The percentage of children 0 to 20 years of age with a newly prescribed antipsychotic during the measurement year who had at least one follow-up care visit with a prescriber within 30 days of that new prescription.
Denominator Ages 0 to < 21 years as of December 31 of the measurement year AND On any antipsychotics medication ( 
The percentage of children 0 to 20 years of age on any antipsychotic who had metabolic screening documented during the measurement year.
Denominator Ages 0 to < 21 years as of December 31 of the measurement year AND On any antipsychotics medication (Table 1) AND Continuously enrolled for at least 3 months AND Benefits: Medical and Pharmacy
Numerator 1
Those who had at least one test for blood glucose [HbA1c test for children with diabetes (Table 4) and either HbA1c or blood glucose for children without diabetes] (Table 5) during the measurement year
Numerator 2
Those who had at least one cholesterol test (Table 6 ) during the measurement year
Numerator 3
Those who had both a test for blood glucose (Table 5) and cholesterol ( 90804-90815, 96150-96154, 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99383, 99384, 99393, 99394, 99401-99404, 99411, 99412, 99510 G0155, G0176, G0177, G0409-G0411, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, M0064, S0201, S9480, S9484, S9485 0510, 0513, 0515-0517, 0519-0523, 0526-0529, 0900, 0902-0905, 0907, 0911-0917, 0919, 0982, 0983 90801, 90802, [90816] [90817] [90818] [90819] [90821] [90822] [90823] [90824] [90826] [90827] [90828] [90829] 90845, 90847, 90849, 90853, 90857, 90862, 90875, 90876 WITH 03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 33, 49, 50, 52, 53, 71, [99231] [99232] [99233] 99238, 99239, [99251] [99252] [99253] [99254] [99255] With 52, 53 
CPT Code POS Code
